Stockreport

bluebird bio Presents New Data for LentiGlobin Gene Therapy in Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology

bluebird bio, Inc.  (BLUE) 
Last bluebird bio, inc. earnings: 2/18 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.bluebirdbio.com/investor-overview
PDF LentiGlobin treatment-derived hemoglobin HbAT87Q equals or exceeds sickling hemoglobin (HbS) levels in Group C patients at six months post treatment [Read more]